| [1] US Food and Drug Administration, Guidance for Industry:PATA Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance, 2004[2] Rosas J., Blanco M., González J., Alcalà M., Talanta, 2012, 97, 163—170[3] Karande A., Heng P., Liew C., Int. J. Pharm., 2010, 396(1/2), 63—74[4] Qiao W. Q., Chem. Res. Chinese Universities, 2012, 28(2), 239—241[5] Sulub Y., LoBrutto R., Vivilecchia R., Wabuyele B., Anal. Chim. Acta, 2008, 611(2), 143—150[6] Li W., Xing L., Fang L., Wang J., Qu H., J. Pharm. Biomed. Anal., 2010, 53(3), 350—358[7] Zhu X. R, Li N., Shi X. Y., Qiao Y. J., Zhang Z. Y., Chem. J. Chinese Universities, 2008, 29(5), 906—911(朱向荣, 李娜, 史新元, 乔延江, 张卓勇. 高等学校化学学报, 2008, 29(5), 906—911)[8] Rosa S., Barata P., Martins J., Menezes J., J. Pharm. Biomed. Anal., 2008, 47(2), 320—327[9] Jin Y., Ding H., Liu X., Wan X., Luan L., Wu Y., Spectrochim. Acta A Mol. Biomol. Spectr., 2013, 109, 68—78[10] Wu Z., Tao O., Dai X., Du M., Shi X., Qiao Y., Vib. Spectrosc., 2012, 63, 371—379[11] Wu Y., Jin Y., Li Y., Sun D., Liu X., Chen Y., Vib. Spectrosc., 2012, 58, 109—118[12] Momose W., Imai K., Yokota S., Yonemochi E., Terada K., Powder Technol., 2011, 210(2), 122—131[13] International Conference on Harmonisation, ICH Q8(R2):Pharmaceutical Development, 2009[14] Wu H., White M., Khan M., Int. J. Pharm., 2011, 405(1/2), 63—78[15] Jiang C., Flansburg L., Ghose S., Jorjorian P., Shukla A., Biotechno. Bioeng., 2010, 107(6), 985—997[16] Hu K., Yuan J., J. Process Contr., 2008, 18, 797—807[17] Huang H., Qu H., Anal. Chim. Acta, 2011, 707, 47—56[18] Wu Z., Xu B., Du M., Sui C., Shi X., Qiao Y., J. Pharm. Biomed. Anal., 2012, 62, 1—6[19] Xu B., Wu Z., Lin Z., Sui C., Shi X., Qiao Y., Anal. Chim. Acta, 2012, 720, 22—28[20] Xu B., Lin Z., Shi X., Qiao Y., Du M., Wu Z., International Conference on Biomedical Engineering and Biotechnology, IEEE Computer Society, Macau, 2012, 1566—1571[21] Puchert T., Holzhauer C., Menezes J., Lochmann D., Reich G., Eur. J. Pharm. Biopharm., 2011, 78(1), 173—182 |
